Skip to main content
CHUGAI PHARMACEUTICAL CO., LTD. logo

CHUGAI PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4519 ISIN · JP3519400000 LEI · 529900T9LAII161DCN95 T Manufacturing
Open in API
Filings indexed 81 across all filing types
Latest filing 2024-07-26 Interim / Quarterly Rep…
Country JP Japan
Listing T 4519

About CHUGAI PHARMACEUTICAL CO., LTD.

https://www.chugai-pharm.co.jp/english/

Chugai Pharmaceutical Co., Ltd. is a research and development-driven pharmaceutical company dedicated to creating innovative medical products to address unmet medical needs. As a member of the Roche Group, Chugai leverages its advanced expertise in biotechnology and science to develop novel treatments, establishing a leading position in therapeutic antibodies. The company's strategy emphasizes a shift towards discovery research and early clinical development, the integration of digital technologies, and open innovation through external partnerships. Its core therapeutic areas include oncology, rheumatology, and haemophilia, where it provides biopharmaceuticals and molecular targeted therapies to patients.

Recent filings

Filing Released Lang Actions
半期報告書－第114期(2024/01/01－2024/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Chugai Pharmaceutical Co., Ltd. with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It covers the interim accounting period from January 1, 2024, to June 30, 2024. It contains comprehensive financial statements, management analysis (MDA), and business information, which fits the definition of an Interim/Quarterly Report (IR). H1 2024
2024-07-26 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document text contains Japanese regulatory headers such as "【提出書類】確認書" (Filing Document: Confirmation Document) and references the "金融商品取引法" (Financial Instruments and Exchange Act). It explicitly states that the CEO and CFO confirm the appropriateness of the contents of the "2023年（自 2023年１月１日 至 2023年12月31日）の有価証券報告書の訂正報告書" (Correction Report for the Securities Report for the fiscal year ended December 31, 2023). This structure—a formal confirmation by top executives regarding the accuracy of a previously filed report (specifically a correction report for a Securities Report, which is equivalent to a 10-K or comprehensive annual filing in the US context)—is characteristic of a formal regulatory filing confirming accuracy, often submitted alongside or as part of the main filing process. Given the options, this document is a formal regulatory confirmation/statement rather than the full report itself. Since it is a formal confirmation related to the annual filing (Securities Report/10-K), and it doesn't fit perfectly into the other specific categories like ER, IR, or AR, it falls best under the general regulatory filing category, RNS, or potentially a specific confirmation type if one existed. However, since the core content is a formal declaration related to the annual filing accuracy, and it is a short confirmation document, RNS (Regulatory Filings) is the most appropriate fallback for specific Japanese regulatory confirmations that aren't standard US forms. If the document were the actual 10-K, the code would be 10-K, but this is a confirmation *of* the 10-K/Securities Report. Given the context of financial document classification, RNS serves as the best fit for miscellaneous, formal regulatory statements.
2024-07-26 Japanese
訂正有価証券報告書－第113期(2023/01/01－2023/12/31)
Regulatory Filings
2024-07-26 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO and CFO regarding the accuracy of the company's quarterly report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS). Q1 2024
2024-04-25 Japanese
四半期報告書－第114期第1四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial statements, management analysis (MDA), and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-04-25 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is extremely short (894 characters) and contains a header structure typical of Japanese regulatory filings, specifically mentioning "【提出書類】確認書" (Filing Document: Confirmation Document) and referencing the Financial Instruments and Exchange Act ("金融商品取引法"). The core content confirms that the CEO and CFO have verified the appropriateness of the contents of the '有価証券報告書' (Securities Report/Annual Report) for the fiscal year ending December 31, 2023. This document is a certification or confirmation related to a previously filed major report (likely a 10-K equivalent in the Japanese context, which is the Annual Securities Report). Since this is a confirmation document accompanying or related to the main annual filing, and it is very brief, it functions as a regulatory confirmation rather than the full report itself. Given the options, this type of confirmation/certification document, which is not a standard financial statement, earnings release, or management discussion, fits best under the general 'Regulatory Filings' (RNS) category, as it is a specific regulatory compliance document that doesn't match the other detailed categories like 10-K (the report being confirmed) or ER/IR. However, upon closer inspection of the definitions, the document is a confirmation of the *Annual Report* (有価証券報告書). While RNS is a fallback, the content strongly relates to the annual reporting cycle. Since the document is a confirmation/certification ('確認書') and not the full Annual Report (10-K), and it is not an announcement of a report's publication (RPA), RNS remains the most appropriate general regulatory filing category for this specific certification document.
2024-04-24 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.